Skip Navigation


Rheumatology Advance Access originally published online on July 20, 2009
Rheumatology 2009 48(10):1183-1184; doi:10.1093/rheumatology/kep216
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
48/10/1183    most recent
kep216v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Santana, A. N. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santana, A. N. C.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial

Circulating endothelial progenitor cells in ANCA-associated vasculitis: the light at the end of the tunnel?

Alfredo N. C. Santana1

1Hospital Regional Publico Araguaia/IDESMA and University of São Paulo, São Paulo, Brazil

Correspondence to: Alfredo N. C. Santana, Rua Maraba 21, CEP 68550-490, Redencao, PA, Brazil. E-mail: alfredonicodemos@hotmail.com

The first 10% of the full text of this article appears below.

The main clinical features of ANCA-associated vasculitis (AAV) are inflammation and necrosis of small vessels, thrombus formation and endothelial injury [1–3]. In this issue of Rheumatology, Závada et al. [4] conclude that low numbers of circulating endothelial progenitor cells (EPCs) are associated with increased propensity for early relapse of AAV.

The therapeutic potential of EPCs in AAV may exist in the form of four different scenarios. First, although disease remission is achieved by most patients, morbidity (pulmonary fibrosis, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?